Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
Interventions: Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution, 64-MDCT Scanning; Drug · Procedure
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions: Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Monterey, California • Orange, California + 19 more

Conditions: Advanced Cancer
Interventions: BMS-986148, Nivolumab; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: La Jolla, California • Durham, North Carolina

Conditions: Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg; Drug
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Pain, Postoperative
Interventions: Single shot interscalene nerve block, Continuous interscalene nerve block, Local Infiltration Analgesia (LIA); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Overweight
Interventions: HU6; Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 16
States / cities: Phoenix, Arizona • Tuscon, Arizona • Anahiem, California + 13 more

Conditions: VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
Interventions: JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg, JNJ-64179375 (Dose to be Determined), JNJ-64179375 A mg/kg, JNJ-64179375 B mg/kg, JNJ-64179375 C mg/kg, JNJ-64179375 D mg/kg, Placebo JNJ-64179375, Apixaban placebo, Apixaban 2.5 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 50 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more

Conditions: Prostate Cancer
Interventions: Kegel exercises, Pelvic Floor Muscle Exercise Program with biofeedback, Questionnaires, Interviews; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Heart Failure
Interventions: Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 1, Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 2; Device
Lead sponsor: Acorai AB; Industry
Eligibility: 18 Years and older
Enrollment: 1,602 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Conway, Arkansas • Little Rock, Arkansas • Jacksonville, Florida + 6 more

Conditions: Vaginal Atrophy, Vaginal Relaxation, Stress Urinary Incontinence
Interventions: Votiva RF; Device
Lead sponsor: Walden, Jennifer L., M.D.,P.L.L.C.; Individual
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New York, New York • Austin, Texas

Conditions: Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Interventions: ONCOS-102, Cyclophosphamide, Pembrolizumab; Biological · Drug
Lead sponsor: Targovax Oy; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: LY3323795, Itraconazole, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Stage IV (Metastatic) Breast Cancer
Interventions: ABI-007, vinorelbine, Trastuzumab, G-CSF; Drug · Biological
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Duarte, California • Seattle, Washington

Conditions: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Relapsed Follicular Lymphoma, Relapsed Marginal Zone Lymphoma, Relapse Diffuse Large B Cell Lymphoma, Relapsed Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Transformation, Refractory Diffuse Large B-cell Lymphoma, Transformed Non-Hodgkin Lymphoma
Interventions: BGB-21447; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Iowa City, Iowa • Waukee, Iowa + 4 more

Conditions: Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin, Hormone Receptor-Positive Breast Cancer
Interventions: CC-223; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more

Conditions: Adolescent Behavior
Interventions: Mighty Girls, Game Girls; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 11 Years to 14 Years · Female only
Enrollment: 552 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions: CT Scan; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Smoking Cessation
Interventions: Wellness Education Control Condition, Mindfulness Training, Mindfulness Training Plus IE; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adolescent Alcohol Use
Interventions: Brief Motivational Interviewing-based Alcohol Intervention, Smartphone App-delivered Mindfulness Training; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years to 17 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Baltimore, Maryland • Belcamp, Maryland • Bowie, Maryland + 6 more

Conditions: Gastrointestinal Stromal Tumors
Interventions: CGT9486, Pexidartinib, Sunitinib; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 6
States / cities: Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 3 more

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321); Drug
Lead sponsor: Bayer; Industry
Eligibility: 50 Years and older
Enrollment: 1,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 57
States / cities: Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more

Conditions: Healthy, Obese
Interventions: LY3502970; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Conditions: Postmenopausal
Interventions: Diet - higher protein, Physical activity and resistance training; Other · Behavioral
Lead sponsor: University of Arkansas, Fayetteville; Other
Eligibility: Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Fayetteville, Arkansas

Search by objective public record fields.

Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

A Study of BMS-986148 in Patients With Select Advanced Solid Tumors

Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate

Analgesic Efficacy of Interscalene Nerve Block Versus Local Infiltration Analgesia Following Total Shoulder Arthroplasty

Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6

A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

A Study of a Pelvic Floor Muscle Exercise Program Before and After Radical Prostatectomy

Acorai Machine Learning Generalization (MLG) Study

Evaluation of Efficacy and Safety of Votiva for Vaginal Rejuvenation

A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade

A Study of LY3323795 in Healthy Participants

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

JUEGA: A Fun Study for Hispanic/Latino Adolescent Girls

DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy

Engaging Working Memory and Distress Tolerance to Aid Smoking Cessation

Brief Motivational Interviewing +/- Mindfulness Training for Adolescent Alcohol Use in Pediatric Primary Care

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Protein and Exercise for Postmenopausal Women's Wellbeing